All In Biotech

Drug Trial Radar · NCT05845450

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Window-of-opportunity Umbrella Platform Trial of Short-course Pre-operative Targeted Treatments in Patients With Molecularly Selected and Resectable Primary Colorectal Cancer: the UNICORN Study

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

197

Planned (sponsor's estimate)

Start

May 11, 2023

Primary completion

May 2027

Study completion May 2028

Sponsor

Lead sponsor
Gruppo Oncologico del Nord-OvestAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a window-of-opportunity umbrella platform trial enrolling non-metastatic resectable colorectal patients selected for the presence of a specific targetable molecular alteration. The study aims to test the activity of specific targeted agents/combinations given as a short-course pre-operative strategy, matched with the specific alteration detected, followed by standard of care surgery.

Conditions

  • Colorectal Cancer
  • Resectable Colorectal Carcinoma

Interventions

  • Trastuzumab deruxtecanDrug

    trastuzumab deruxtecan 5.4 mg/kg IV on day 1

  • DurvalumabDrug

    durvalumab 1500 mg IV on day 1

  • PanitumumabDrug

    panitumumab 6 mg/kg IV on days 1 and 15

  • BotensilimabDrug

    botensilimab 1 mg/kg on day 1

  • BalstilimabDrug

    balstilimab 3 mg/Kg on days 1 and 15

  • SotorasibDrug

    sotorasib 960 mg orally once daily from day 1 to 28

  • VorbipiprantDrug

    vorbipiprant 90 mg orally bid from day 1 to 28

  • NivolumabDrug

    240 mg IV on days 1 and 15

  • AmivantamabDrug

    amivantamab at the dose of 1600 mg (2240 mg if body weight ≥ 80 Kg), subcutaneously, on days 1, 8, 15 and 22

  • BotensilimabDrug

    Botensilimab at the dose of 75 mg, IV on day 1

  • BalstilimabDrug

    balstilimab at the dose of 240 mg, IV on days 1, 15, 29 and 43

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. major pathological response rateTime frame: 5 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

    Milan, Lombardia/MI, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.